近十年來，乳癌新輔助化療的應用日益擴大。對新輔助化療反應良好的患者可受益於乳房及腋窩手術的降階治療。然而，乳房腫瘤及受累腋窩淋巴結應在化療開始前進行標記。這有助於後續手術規劃及術中評估疾病反應。
適應症：Breast Neoplasm、Chemotherapy Effect
收案條件
納入條件
- All patients with cT1-3N1 invasive ductal carcinoma planned for neoadjuvant chemotherapy and/or target therapy
- mentally competent to give informed consent
- Agreed to proceed with curative operation after chemotherapy and tentatively keen for breast conservative surgery and targeted axillary dissection after neoadjuvant chemotherapy
- Radiologically 1-3 ipsilateral axillary lymph node metastases confirmed by cytology or biopsy
排除條件
- Presence of distant metastasis, inflammatory breast cancers, multi-centric breast cancers
- History of previous ipsilateral axillary surgery or irradiation
- Hypersensitivity to dextran compounds or iron
- Iron overload disease
- Pregnant or lactating patients
- Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder
- Mentally incompetent patients
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。